# Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

> **NCT03392389** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 124 (actual)

## Conditions studied

- Human Metapneumovirus and Human Parainfluenza Infection

## Interventions

- **BIOLOGICAL:** mRNA-1653
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03392389
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2019-07-29
- **Final completion:** 2019-07-29
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03392389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03392389, "Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03392389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*